바이오뱅크 시장 규모, 점유율, 동향 분석 리포트 : 제품·서비스별, 생체 시료 유형별, 바이오뱅크 유형별, 용도별, 지역별, 부문별 예측(2025-2030년)

Biobanks Market Growth & Trends:

The global biobanks market size is expected to reach USD 126.69 billion in 2030 and is expected to grow at a CAGR of 7.85% from 2025 to 2030, according to a new report by Grand View Research, Inc. Biobanks continue to evolve with the introduction of new technologies, such as NGS, and increased focus on genomic medicine. The availability of several types of biospecimens to cater to multiple domains including drug discovery, diagnostics, and others has accelerated the diversification of biorepositories, thereby driving the market. The quality of biospecimens can significantly influence disease testing as well as preclinical and clinical research. Regulatory agencies have played a vital role in spurring the adoption of biobanking services by establishing guidelines for the effective management of samples.

For instance, the U.S. Centers for Disease Control and Prevention (CDC) released guidelines to minimize human hazards while handling COVID-19 samples. This serves as a model for other biorepositories. Furthermore, as the number of research studies and clinical trials related to COVID-19 is increasing, the demand for high-quality biospecimens is expected to significantly increase in the near future, leading to market growth. In addition, population-based cohort studies are facilitated by biorepositories to estimate the actual seroprevalence. Health Catalyst, Inc., through its Touchstone platform, provides national data related to COVID-19 insights. Such factors are anticipated to contribute to the revenue flow in this space.

The 'BioResource' was created in October 2021 by RareCan, a Hexham-based healthcare start-up dedicated to improving studies into the uncommon forms of cancer. BioResource will retain samples taken after surgery from cancer patients and make them accessible to researchers across the globe who can use them to cure, prevent, and identify the disease. In December 2021, Newcastle University introduced a new collection of human blood samples and donated human tissue, which could transform efforts to cure rare cancers. The U.K. Biobank has announced that fresh data from a study measuring the range of circulatory metabolomics biomarkers has been added to its database. Nightingale Health, a Finnish business specializing in blood biomarker technologies, conducted the study with 120000 participants.

North America dominated the market with its wide network of centers for biosample storage in the U.S. Moreover, a high number of COVID-19 cases in the U.S. and increased R&D programs have resulted in the establishment of new biorepositories, thereby driving revenue in North America. In Asia Pacific, the market is anticipated to register the fastest growth owing to the ever-expanding pharmaceuticals and clinical research domain across Asian countries. The key players are engaged in expanding their global reach by partnering with global distributors, mergers, and acquisitions of other players, and entering a strategic alliance with research communities.

Biobanks Market Report Highlights:

• The biobanking equipment segment accounted for the maximum revenue share in 2024 owing to the high cost of instruments coupled with an increase in the number of biorepositories
• The biobanking and repository services segment accounted for the largest revenue share in 2024 due to the higher penetration of these services and the increased need for the preservation of biosamples for developing precision medicine and disease-specific research
• Human tissues are the most stored sample for clinical research, resulting in the dominance of this sample type in the market
• The virtual biobanks segment is anticipated to witness the fastest CAGR during the forecast period owing to the growing demand for 3D biospecimens coupled with the need for rare disease data for biomedical research
• The therapeutics application segment accounted for the largest revenue share in 2024 owing to the growing popularity of cell therapies for cancer treatment
• Several pharma/biotech companies have established their private banks to support clinical trials and the development of cell therapies, resulting in revenue growth in this segment.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Product & Services
  • 1.2.2. Biospecimen Type
  • 1.2.3. Biobanks Type
  • 1.2.4. Application
• 1.3. Research Methodology
• 1.4. Information Procurement
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. List of Secondary Sources
• 1.8. List of Primary Sources
• 1.9. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. Biobanks Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Continuous increase in COVID-19 cases along with capacity expansion
    • 3.2.1.2. Increased focus on precision medicine and genetic testing
    • 3.2.1.3. Changes in biobanking operations
    • 3.2.1.4. Increase in the number of clinical trials globally
    • 3.2.1.5. Growing industry and research collaborations
    • 3.2.1.6. Technology advancement and automation
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. Disruptions in supply chain management due to COVID-19
    • 3.2.2.2. Challenges in sharing biobanking data & limited access to biospecimens
    • 3.2.2.3. Sustainability challenges for biobanks
    • 3.2.2.4. Other challenges in biobanking specimens for research
• 3.3. Biobanks Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
  • 3.3.2. PESTEL Analysis

Chapter 4. Biobanks Market: Product & Services Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Product & Services Market Share, 2024 & 2030
• 4.3. Product
• 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 4.4.1. Biobank Equipment
    • 4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.1.2. Temperature Control Systems
      • 4.4.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.1.2.2. Freezers & Refrigerators
        • 4.4.1.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.1.2.3. Cryogenic Storage Systems
      • 4.4.1.2.4. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.1.2.5. Thawing Equipment
      • 4.4.1.2.6. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.1.3. Incubators & Centrifuges
      • 4.4.1.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.1.4. Alarms & Monitoring Systems
      • 4.4.1.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.1.5. Accessories & Other Equipment
      • 4.4.1.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.2. Biobanking Consumables
    • 4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.3. Laboratory Information Management Systems
    • 4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.5. Services
• 4.6. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 4.6.1. Biobanking & repository
    • 4.6.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.6.2. Lab processing
    • 4.6.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.6.3. Qualification/ Validation
    • 4.6.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.6.4. Cold Chain Logistics
    • 4.6.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.6.5. Other Services
    • 4.6.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Biobanks Market: Biospecimen Type Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Biospecimen Type Market Share, 2024 & 2030
• 5.3. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 5.3.1. Human Tissues
    • 5.3.1.1. Market estimates and forecasts 2018 to 2030 (USD million)
  • 5.3.2. Human Organs
    • 5.3.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.3.3. Stem Cells
    • 5.3.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.3.3.2. Adult Stem Cells
      • 5.3.3.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.3.3.3. Embryonic Stem Cells
      • 5.3.3.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.3.3.4. IPS Cells
      • 5.3.3.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.3.3.5. Other Stem Cells
      • 5.3.3.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.3.4. Other biospecimens
    • 5.3.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Biobanks Market: Biobanks Type Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Biobanks Type Market Share, 2024 & 2030
• 6.3. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 6.3.1. Physical/Real biobanks
    • 6.3.1.1. Market estimates and forecasts 2018 to 2030 (USD million)
    • 6.3.1.2. Tissue Biobanks
      • 6.3.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.3.1.3. Population based biobanks
      • 6.3.1.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.3.1.4. Genetic (DNA/RNA)
      • 6.3.1.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.3.1.5. Disease based biobanks
      • 6.3.1.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.3.2. Virtual biobanks
    • 6.3.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Biobanks Market: Application Estimates & Trend Analysis

• 7.1. Segment Dashboard
• 7.2. Application Market Share, 2024 & 2030
• 7.3. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 7.3.1. Therapeutics
    • 7.3.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.3.2. Drug discovery & clinical research
    • 7.3.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.3.3. Clinical Diagnostics
    • 7.3.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.3.4. Other Applications
    • 7.3.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Biobanks Market: Regional Estimates & Trend Analysis

• 8.1. Regional Market Dashboard
• 8.2. Regional Market Share Analysis, 2024 & 2030
• 8.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 8.4. North America
  • 8.4.1. U.S.
    • 8.4.1.1. Key country dynamics
    • 8.4.1.2. Regulatory framework/ reimbursement structure
    • 8.4.1.3. Competitive scenario
    • 8.4.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4.2. Canada
    • 8.4.2.1. Key country dynamics
    • 8.4.2.2. Regulatory framework/ reimbursement structure
    • 8.4.2.3. Competitive scenario
    • 8.4.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4.3. Mexico
    • 8.4.3.1. Key country dynamics
    • 8.4.3.2. Regulatory framework/ reimbursement structure
    • 8.4.3.3. Competitive scenario
    • 8.4.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
• 8.5. Europe
  • 8.5.1. UK
    • 8.5.1.1. Key country dynamics
    • 8.5.1.2. Regulatory framework/ reimbursement structure
    • 8.5.1.3. Competitive scenario
    • 8.5.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.2. Germany
    • 8.5.2.1. Key country dynamics
    • 8.5.2.2. Regulatory framework/ reimbursement structure
    • 8.5.2.3. Competitive scenario
    • 8.5.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.3. France
    • 8.5.3.1. Key country dynamics
    • 8.5.3.2. Regulatory framework/ reimbursement structure
    • 8.5.3.3. Competitive scenario
    • 8.5.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.4. Italy
    • 8.5.4.1. Key country dynamics
    • 8.5.4.2. Regulatory framework/ reimbursement structure
    • 8.5.4.3. Competitive scenario
    • 8.5.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.5. Spain
    • 8.5.5.1. Key country dynamics
    • 8.5.5.2. Regulatory framework/ reimbursement structure
    • 8.5.5.3. Competitive scenario
    • 8.5.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.6. Norway
    • 8.5.6.1. Key country dynamics
    • 8.5.6.2. Regulatory framework/ reimbursement structure
    • 8.5.6.3. Competitive scenario
    • 8.5.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.7. Sweden
    • 8.5.7.1. Key country dynamics
    • 8.5.7.2. Regulatory framework/ reimbursement structure
    • 8.5.7.3. Competitive scenario
    • 8.5.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.8. Denmark
    • 8.5.8.1. Key country dynamics
    • 8.5.8.2. Regulatory framework/ reimbursement structure
    • 8.5.8.3. Competitive scenario
    • 8.5.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
• 8.6. Asia Pacific
  • 8.6.1. Japan
    • 8.6.1.1. Key country dynamics
    • 8.6.1.2. Regulatory framework/ reimbursement structure
    • 8.6.1.3. Competitive scenario
    • 8.6.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.2. China
    • 8.6.2.1. Key country dynamics
    • 8.6.2.2. Regulatory framework/ reimbursement structure
    • 8.6.2.3. Competitive scenario
    • 8.6.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.3. India
    • 8.6.3.1. Key country dynamics
    • 8.6.3.2. Regulatory framework/ reimbursement structure
    • 8.6.3.3. Competitive scenario
    • 8.6.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.4. Australia
    • 8.6.4.1. Key country dynamics
    • 8.6.4.2. Regulatory framework/ reimbursement structure
    • 8.6.4.3. Competitive scenario
    • 8.6.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.5. South Korea
    • 8.6.5.1. Key country dynamics
    • 8.6.5.2. Regulatory framework/ reimbursement structure
    • 8.6.5.3. Competitive scenario
    • 8.6.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.6. Thailand
    • 8.6.6.1. Key country dynamics
    • 8.6.6.2. Regulatory framework/ reimbursement structure
    • 8.6.6.3. Competitive scenario
    • 8.6.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
• 8.7. Latin America
  • 8.7.1. Brazil
    • 8.7.1.1. Key country dynamics
    • 8.7.1.2. Regulatory framework/ reimbursement structure
    • 8.7.1.3. Competitive scenario
    • 8.7.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7.2. Argentina
    • 8.7.2.1. Key country dynamics
    • 8.7.2.2. Regulatory framework/ reimbursement structure
    • 8.7.2.3. Competitive scenario
    • 8.7.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 8.8. MEA
  • 8.8.1. South Africa
    • 8.8.1.1. Key country dynamics
    • 8.8.1.2. Regulatory framework/ reimbursement structure
    • 8.8.1.3. Competitive scenario
    • 8.8.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.8.2. Saudi Arabia
    • 8.8.2.1. Key country dynamics
    • 8.8.2.2. Regulatory framework/ reimbursement structure
    • 8.8.2.3. Competitive scenario
    • 8.8.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.8.3. UAE
    • 8.8.3.1. Key country dynamics
    • 8.8.3.2. Regulatory framework/ reimbursement structure
    • 8.8.3.3. Competitive scenario
    • 8.8.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.8.4. Kuwait
    • 8.8.4.1. Key country dynamics
    • 8.8.4.2. Regulatory framework/ reimbursement structure
    • 8.8.4.3. Competitive scenario
    • 8.8.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Company/Competition Categorization
• 9.2. Strategy Mapping
• 9.3. Company Market Position Analysis, 2024
• 9.4. Company Profiles/Listing
  • 9.4.1. Thermo Fisher Scientific Inc.
    • 9.4.1.1. Company overview
    • 9.4.1.2. Financial performance
    • 9.4.1.3. Product benchmarking
    • 9.4.1.4. Strategic initiatives
  • 9.4.2. Merck KGaA
    • 9.4.2.1. Company overview
    • 9.4.2.2. Financial performance
    • 9.4.2.3. Product benchmarking
    • 9.4.2.4. Strategic initiatives
  • 9.4.3. Qiagen
    • 9.4.3.1. Company overview
    • 9.4.3.2. Financial performance
    • 9.4.3.3. Product benchmarking
    • 9.4.3.4. Strategic initiatives
  • 9.4.4. Hamilton Company
    • 9.4.4.1. Company overview
    • 9.4.4.2. Financial performance
    • 9.4.4.3. Product benchmarking
    • 9.4.4.4. Strategic initiatives
  • 9.4.5. Tecan Trading AG
    • 9.4.5.1. Company overview
    • 9.4.5.2. Financial performance
    • 9.4.5.3. Product benchmarking
    • 9.4.5.4. Strategic initiatives
  • 9.4.6. Danaher Corporation
    • 9.4.6.1. Company overview
    • 9.4.6.2. Financial performance
    • 9.4.6.3. Product benchmarking
    • 9.4.6.4. Strategic initiatives
  • 9.4.7. Becton, Dickinson, and Company (BD)
    • 9.4.7.1. Company overview
    • 9.4.7.2. Financial performance
    • 9.4.7.3. Product benchmarking
    • 9.4.7.4. Strategic initiatives
  • 9.4.8. Biocision, LLC.
    • 9.4.8.1. Company overview
    • 9.4.8.2. Financial performance
    • 9.4.8.3. Product benchmarking
    • 9.4.8.4. Strategic initiatives
  • 9.4.9. Taylor-Wharton
    • 9.4.9.1. Company overview
    • 9.4.9.2. Financial performance
    • 9.4.9.3. Product benchmarking
    • 9.4.9.4. Strategic initiatives
  • 9.4.10. Charles River Laboratories
    • 9.4.10.1. Company overview
    • 9.4.10.2. Financial performance
    • 9.4.10.3. Product benchmarking
    • 9.4.10.4. Strategic initiatives
  • 9.4.11. Lonza
    • 9.4.11.1. Company overview
    • 9.4.11.2. Financial performance
    • 9.4.11.3. Product benchmarking
    • 9.4.11.4. Strategic initiatives
  • 9.4.12. Stemcell Technologies
    • 9.4.12.1. Company overview
    • 9.4.12.2. Financial performance
    • 9.4.12.3. Product benchmarking
    • 9.4.12.4. Strategic initiatives
  • 9.4.13. Biovault Family
    • 9.4.13.1. Company overview
    • 9.4.13.2. Financial performance
    • 9.4.13.3. Product benchmarking
    • 9.4.13.4. Strategic initiatives
  • 9.4.14. Promocell GmbH
    • 9.4.14.1. Company overview
    • 9.4.14.2. Financial performance
    • 9.4.14.3. Product benchmarking
    • 9.4.14.4. Strategic initiatives
  • 9.4.15. Precision Cellular Storage Ltd. (Virgin Health Bank)
    • 9.4.15.1. Company overview
    • 9.4.15.2. Financial performance
    • 9.4.15.3. Product benchmarking
    • 9.4.15.4. Strategic initiatives